Stay updated with breaking news from Wealth Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns […]
StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a research report report published on Monday. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Monday. Read Our Latest Research Report […]
JS Global Capital has been appointed the authorised participant and market maker of the ETF.
Advice firms that do not have a client portal are less valuable to potential buyers than those that do. That was the view of those taking part in a panel discussion on the subject at the Empowering Advice Through Technology (EATT) conference in London today. Research conducted in advance of the conference revealed
Aberdeen chartered financial planning trainee Kelly Shek, of AAB Wealth, says they need to be a good listener for starters.